Freenome, Inc. (FRNM) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $11.16: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend.
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for... Read more
Sell if holding. Engine safety override at $11.16: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 3.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.16: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $10.37. Score 3.7/10, moderate confidence.
Take-profit target: $13.97 (+25.3% upside). Prior stop was $10.37. Stop-loss: $10.37.
Quality below floor (3.2 < 4.0).
Freenome, Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 0.0/10. Verdict: Sell.
What does Freenome, Inc. do?Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection...
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.